Pulse Biosciences, Inc

Item 8.01 Other Events. On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) announced completion of patient enrollment in its PRECISE-BTN clinical study evaluating the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (the “Study”). In addition, the Company announced that the first patient enrolled in the Study had completed their final 12-month follow-up visit. Enrollment was completed following an expansion of the Study from its original 50-patient design to 100 patients. All patients were enrolled across three U.S. clinical sites - Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine - within approximately 12 months. The Study protocol specifies follow-up visits at one, three, six, and twelve months post-procedure and endpoints include safety, targeted nodule volume reduction, symptomatic relief, hormone normalization, and improvements in quality of life. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.